Plain-English translation of NCT07044297 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new HIV prevention medication called that you would take once a month, instead of every day like current prevention pills. Researchers want to see if this monthly treatment works just as well — or better — than the standard daily pill at preventing HIV infection, and whether it's safe and easy to tolerate.
Current HIV prevention pills require daily doses, which can be hard for some people to remember and stick with. A once-monthly option could make it easier for people to protect themselves from HIV infection.
You would be randomly assigned to receive either the new once-monthly medication plus a daily placebo, or the standard daily prevention pill plus a monthly placebo, for about 2 years. This keeps the study blinded so neither you nor the researchers know which treatment you're getting. You'll attend regular study visits for testing and monitoring, and at the end, everyone will receive the standard daily pill for an additional 28 days.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States